MCID: ACT008
MIFTS: 51

Actinic Keratosis malady

Categories: Skin diseases, Cancer diseases

Aliases & Classifications for Actinic Keratosis

Aliases & Descriptions for Actinic Keratosis:

Name: Actinic Keratosis 12 52 14 69
Senile Hyperkeratosis 12
Seborrheic Keratosis 69
Sk - Solar Keratosis 12
Actinic Keratosis 12
Keratosis, Actinic 42
Solar Keratosis 12

Classifications:



Summaries for Actinic Keratosis

MalaCards based summary : Actinic Keratosis, also known as senile hyperkeratosis, is related to infiltrative basal cell carcinoma and keratosis. An important gene associated with Actinic Keratosis is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Mitotic G1-G1/S phases and MicroRNAs in cancer. The drugs Picato gel and Aminolevulinic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and kidney, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and growth/size/body region

Wikipedia : 71 Actinic keratosis (also called solar keratosis and senile keratosis; abbreviated as AK) is a... more...

Related Diseases for Actinic Keratosis

Diseases related to Actinic Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
id Related Disease Score Top Affiliating Genes
1 infiltrative basal cell carcinoma 29.7 KRT17 KRT20
2 keratosis 11.6
3 actinic cheilitis 11.1
4 squamous cell carcinoma 10.6
5 basal cell carcinoma 10.5
6 clear cell adenofibroma 10.3 CDKN2A TP53
7 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
8 bowen's disease 10.3
9 bile duct clear cell adenocarcinoma 10.3 PTGS2 TP53
10 neuropathy, hereditary sensory, type id 10.3 MMP14 MMP2
11 anisomastia 10.3 MMP14 MMP2
12 spondylarthropathy 10.3 CDKN2A TP53
13 acquired hemangioma 10.2 CDKN2A PTGS2 TP53
14 urethral verrucous carcinoma 10.2 CDKN2A PTGS2 TP53
15 pericardium leiomyoma 10.2 CDKN2A PCNA TP53
16 tamoxifen-related endometrial lesion 10.2 CDKN2A PTGS2 TP53
17 nodular cutaneous amyloidosis 10.2 CDKN2A MMP2 TP53
18 oro-mandibular-limb hypogenesis syndrome 10.2 CDKN2A PCNA TP53
19 maxillary sinus cholesteatoma 10.2 CDKN2A MMP2 TP53
20 paraphimosis 10.2 CDKN2A KRT20 TP53
21 flat ductal epithelial atypia 10.2 CDKN2A TNC TP53
22 spastic ataxia 5 10.2 CDKN2A KRT20 TP53
23 linear porokeratosis 10.2 MMP14 MMP2 TNC
24 radiculopathy 10.2 KRT20 TP63
25 subglottis neoplasm 10.2 CDKN2A MMP14 MMP2
26 progesterone-receptor positive breast cancer 10.2 CDKN2A PTGS2 TP53
27 pacinian tumor 10.2 CDKN2A KRT20 TP53
28 uterine cervix leukoplakia 10.2 CDKN2A KRT17 TP53
29 placental site trophoblastic tumor 10.2 CDKN2A KRT20 TP53
30 thymus squamous cell carcinoma 10.2 CDKN2A KRT17 TP53
31 allergic contact dermatitis 10.2 CDKN2A KRT20 TP53
32 vestibular gland benign neoplasm 10.2 CDKN2A PTGS2 TP53
33 melanoma 10.2
34 trachea squamous cell carcinoma 10.2 CDKN2A MMP2 TP53
35 pancreatic gastrinoma 10.2 KRT17 KRT20
36 estrogen-receptor positive breast cancer 10.2 CDKN2A KRT17 TP53
37 plasmodium ovale malaria 10.2 CDKN2A TP53 TP63
38 pyomyositis 10.2 CDKN2A KRT17 TP53
39 facial dermatosis 10.2 CDKN2A PTGS2 TP53
40 small intestine leiomyoma 10.2 KRT17 KRT20 TP53
41 leukoencephalopathy palmoplantar keratoderma 10.2 MC1R MMP2
42 pituitary carcinoma 10.2 KRT20 PTGS2 TP53
43 oral squamous cell carcinoma 10.2 KRT20 PTGS2 TP53
44 clear cell hidradenoma 10.2 KRT20 TP53
45 lattice corneal dystrophy 10.2 CDKN2A MMP2 PTGS2 TP53
46 childhood-onset cerebral x-linked adrenoleukodystrophy 10.2 CDKN2A TP53 TP63
47 sarcomatoid basal cell carcinoma 10.2 KRT17 KRT20 TP53
48 hepatic flexure cancer 10.1 CDKN2A MMP2 TP53
49 proctitis 10.1 CDKN2A MMP2 PTGS2 TP53
50 dysembryoplastic neuroepithelial tumor 10.1 KRT20 PTGS2 TP53

Graphical network of the top 20 diseases related to Actinic Keratosis:



Diseases related to Actinic Keratosis

Symptoms & Phenotypes for Actinic Keratosis

GenomeRNAi Phenotypes related to Actinic Keratosis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 PCNA TP53 CDKN2A CFLAR MCM2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 PCNA TP53 TP63 CDKN2A CFLAR MCM2

MGI Mouse Phenotypes related to Actinic Keratosis:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 CDKN2A CFLAR KRT17 LUM MC1R MCM2
2 cellular MP:0005384 10.26 CDKN2A CFLAR KRT17 LUM MC1R MCM2
3 behavior/neurological MP:0005386 10.23 CDKN2A LUM MC1R MCM2 MMP14 PTGS2
4 immune system MP:0005387 10.2 MMP14 MMP2 PCNA PTGS2 TP53 TP63
5 hematopoietic system MP:0005397 10.18 CDKN2A CFLAR LUM MC1R MCM2 MMP14
6 cardiovascular system MP:0005385 10.17 CDKN2A CFLAR LUM MMP14 MMP2 PTGS2
7 digestive/alimentary MP:0005381 10.14 CDKN2A KRT17 LUM MCM2 MMP14 PTGS2
8 endocrine/exocrine gland MP:0005379 10.11 CDKN2A CFLAR MCM2 MMP14 PCNA PTGS2
9 integument MP:0010771 10.09 CDKN2A KRT17 LUM MC1R MCM2 MMP14
10 embryo MP:0005380 10.07 MCM2 MMP14 PTGS2 TP53 TP63 CDKN2A
11 muscle MP:0005369 10.06 CDKN2A CFLAR LUM MCM2 MMP14 MMP2
12 craniofacial MP:0005382 10.02 KRT17 MC1R MMP14 MMP2 TP53 TP63
13 no phenotypic analysis MP:0003012 9.97 TNC TP53 TP63 CDKN2A KRT17 MC1R
14 neoplasm MP:0002006 9.91 TP53 TP63 CDKN2A MC1R MCM2 MMP2
15 normal MP:0002873 9.8 TP63 MCM2 MMP14 MMP2 PTGS2 TNC
16 pigmentation MP:0001186 9.55 CDKN2A KRT17 MC1R MCM2 TP53
17 respiratory system MP:0005388 9.5 TP63 CDKN2A MCM2 MMP14 MMP2 PTGS2
18 vision/eye MP:0005391 9.17 CDKN2A LUM MMP14 MMP2 PTGS2 TP53

Drugs & Therapeutics for Actinic Keratosis

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Picato gel 17 INGENOL MEBUTATE LEO Pharma Approved January 2012

Drugs for Actinic Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 3,Early Phase 1 51-21-8 3385
4
Ethanol Approved Phase 4,Phase 2 64-17-5 702
5
Bezafibrate Approved Phase 4 41859-67-0 39042
6
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
7
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 1 15307-86-5 3033
8
Salicylic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 69-72-7 338
9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
11
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
12
Menthol Approved Phase 4 2216-51-5 16666
13
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
14
Cyclosporine Approved, Investigational, Vet_approved Phase 4 79217-60-0, 59865-13-3 5284373 6435893
15
Mycophenolic acid Approved Phase 4 24280-93-1 446541
16
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
17
Azathioprine Approved Phase 4 446-86-6 2265
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 11103-57-4, 68-26-8 445354
19
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
20
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
21 interferons Phase 4,Phase 3,Phase 2,Phase 1
22 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
23 Sunscreening Agents Phase 4,Phase 3,Phase 2
24 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
26 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Protective Agents Phase 4,Phase 3,Phase 2
29 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
30 Radiation-Protective Agents Phase 4,Phase 2
31 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
32 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1
34 vitamin d Phase 4,Phase 1
35 Clofibric Acid Phase 4 882-09-7
36 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
37
Alginic acid Phase 4 9005-32-7
38 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
39 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
40 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Emollients Phase 4,Phase 3,Phase 2,Early Phase 1
43 Viscosupplements Phase 4
44 Ergocalciferols Phase 4,Phase 1
45 Vitamins Phase 4,Phase 2,Phase 1,Early Phase 1
46 Hypolipidemic Agents Phase 4,Phase 2
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Anticholesteremic Agents Phase 4,Phase 2
49 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 318)
id Name Status NCT ID Phase
1 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Unknown status NCT01538901 Phase 4
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4
3 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
4 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4
5 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Completed NCT00116649 Phase 4
6 Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4
7 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4
8 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis Completed NCT02716714 Phase 4
9 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed NCT00110682 Phase 4
10 Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Completed NCT00115154 Phase 4
11 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
12 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4
13 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses Completed NCT00777127 Phase 4
14 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4
15 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4
16 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4
17 Effects of Topical Diclofenac on Tumor Metabolism Completed NCT01935531 Phase 4
18 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4
19 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4
20 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4
21 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4
22 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
23 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4
24 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Recruiting NCT02647151 Phase 4
25 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Recruiting NCT02281682 Phase 4
26 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Recruiting NCT02866695 Phase 4
27 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Active, not recruiting NCT02464709 Phase 4
28 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Active, not recruiting NCT02622594 Phase 4
29 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4
30 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4
31 Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy Not yet recruiting NCT02990221 Phase 4
32 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4
33 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4
34 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4
35 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4
36 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4
37 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3
38 5fluorouracil for Advanced Photoaging Unknown status NCT01405144 Phase 3
39 A Study of the Clinicopathologic Behaviour of the Different Types of Unsafe Chronic Otitis Media Unknown status NCT00270660 Phase 3
40 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3
41 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00742391 Phase 3
42 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00942604 Phase 3
43 Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment Completed NCT01459393 Phase 3
44 A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) Completed NCT00915551 Phase 3
45 A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) Completed NCT00916006 Phase 3
46 Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp Completed NCT00304239 Phase 3
47 Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp Completed NCT00306800 Phase 3
48 Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses Completed NCT02289768 Phase 3
49 Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities Completed NCT02137785 Phase 3
50 Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis Completed NCT02616601 Phase 3

Search NIH Clinical Center for Actinic Keratosis

Cochrane evidence based reviews: keratosis, actinic

Genetic Tests for Actinic Keratosis

Anatomical Context for Actinic Keratosis

MalaCards organs/tissues related to Actinic Keratosis:

39
Skin, T Cells, Kidney, Testes, Eye

Publications for Actinic Keratosis

Articles related to Actinic Keratosis:

(show top 50) (show all 535)
id Title Authors Year
1
CD40 Ligand Is Increased in Mast Cells in Psoriasis and Actinic Keratosis but Less So in Epithelial Skin Carcinomas. ( 28267402 )
2017
2
Predictors of actinic keratosis count in patients with multiple keratinocyte carcinomas: A cross-sectional study. ( 28088997 )
2017
3
A seamless Phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp. ( 28078678 )
2017
4
Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update. ( 27785771 )
2017
5
Acantholytic squamous cell carcinoma is usually associated with hair follicles, not acantholytic actinic keratosis, and is not "high risk": Diagnosis, management, and clinical outcomes in a series of 115 cases. ( 27889291 )
2017
6
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017
7
Photodynamic therapy in the management of actinic keratosis: Retrospective evaluation of outcome. ( 27174210 )
2016
8
Pain evaluation in patients affected by cutaneous squamous cell carcinoma and actinic keratosis: an observational study. ( 27096539 )
2016
9
Italian expert consensus for the management of actinic keratosis in immunocompetent patients. ( 27060910 )
2016
10
PDT and emerging therapies for Actinic Keratosis-A resource letter. ( 27613999 )
2016
11
Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study. ( 27046744 )
2016
12
Adherence to topical therapies in actinic keratosis: A literature review. ( 27161045 )
2016
13
Histopathology and reflectance confocal microscopy features of photodamaged skin and actinic keratosis. ( 27298142 )
2016
14
Electrospun poly-l-lactide scaffold for the controlled and targeted delivery of a synthetically obtained Diclofenac prodrug to treat actinic keratosis. ( 27816622 )
2016
15
Costs of Keratinocyte Carcinoma (Nonmelanoma Skin Cancer) and Actinic Keratosis Treatment in the Veterans Health Administration. ( 27465252 )
2016
16
Ingenol Disoxate: A Novel 4-Isoxazolecarboxylate Ester of Ingenol with Improved Properties for Treatment of Actinic Keratosis and Other Non-Melanoma Skin Cancers. ( 27503482 )
2016
17
A new algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma based on in vivo analysis of optical properties by high-definition optical coherence tomography. ( 27311752 )
2016
18
Survey of Patient Satisfaction With Ingenol Mebutate Gel Treatment for Actinic Keratosis From a Community Dermatology Practice. ( 27784514 )
2016
19
Case of Japanese Hermansky-Pudlak syndrome patient with deeply invasive squamous cell carcinoma and multiple lesions of actinic keratosis on the face and neck. ( 27178242 )
2016
20
Prevalence of actinic keratosis among dermatology outpatients in Spain. ( 27445129 )
2016
21
Feasibility of daylight-mediated photodynamic therapy for actinic keratosis throughout the year in Central and South America: a meteorological study. ( 27061814 )
2016
22
Pigmentation-Independent Susceptibility Loci for Actinic Keratosis Highlighted by Compound Heterozygosity Analysis. ( 27646882 )
2016
23
Cytokeratin 17 immunoexpression in actinic keratosis (bowenoid and nonbowenoid) and in Bowen disease. ( 26740287 )
2016
24
Defining Field Cancerization of the Skin Using Noninvasive Optical Coherence Tomography Imaging to Detect and Monitor Actinic Keratosis in Ingenol Mebutate 0.015%- Treated Patients. ( 27386042 )
2016
25
Expression of Podoplanin in Non-melanoma Skin Cancers and Actinic Keratosis. ( 27069135 )
2016
26
Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolevulinic acid photodynamic therapy for the treatment of multiple actinic keratosis. ( 28012181 )
2016
27
Mycosis fungoides patient accompanied actinic keratosis, actinic keratosis with squamous cell carcinoma transformation, and porokeratosis after NBUVB therapy - 1st case report and review of the literature. ( 27741114 )
2016
28
Diagnostic accuracy of optical coherence tomography in actinic keratosis and basal cell carcinoma. ( 27519350 )
2016
29
Bucher's indirect comparison of daylight photodynamic therapy with methyl aminolevulinate cream versus diclofenac plus hyaluronic acid gel for the treatment of multiple actinic keratosis. ( 27352420 )
2016
30
Egg membrane may protect eyes from ALA photodynamic therapy for eyelid actinic keratosis: Two case reports. ( 27350169 )
2016
31
Variables in Cryosurgery Technique Associated With Clearance of Actinic Keratosis. ( 28002105 )
2016
32
Validation of a diagnostic algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma by means of high-definition optical coherence tomography. ( 27095632 )
2016
33
Actinic Keratosis Pathogenesis Update and New Patents. ( 27142784 )
2016
34
Actinic Keratosis. ( 27046367 )
2016
35
Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain. ( 27130804 )
2016
36
The continued use of sunscreen prevents the development of actinic keratosis in aged Japanese subjects. ( 27539900 )
2016
37
Use of Lesion Response Rate in Actinic Keratosis Trials. ( 27645828 )
2016
38
Ablative non-sequential fractional ultrapulsed CO2 laser pretreatment improves conventional photodynamic therapy with methyl aminolevulinate in a novel human in vitro 3D actinic keratosis skin model. ( 27194644 )
2016
39
Actinic keratosis as a marker of field cancerization in excision specimens of cutaneous malignancies. ( 27416085 )
2016
40
Ingenol mebutate in actinic keratosis: a clinical, videodermoscopic and immunohistochemical study. ( 27453064 )
2016
41
Actinic keratosis in China: big numbers and small percentages. ( 27206355 )
2016
42
The current role of in vivo reflectance confocal microscopy within the continuum of actinic keratosis and squamous cell carcinoma: a systematic review. ( 28007674 )
2016
43
MAL Daylight Photodynamic Therapy for Actinic Keratosis: Clinical and Imaging Evaluation by 3D Camera. ( 27409613 )
2016
44
Bowenoid Actinic Keratosis and Bowen's Disease Treated Successfully with Ingenol Mebutate. ( 27513957 )
2016
45
Actinic keratosis-related signs predictive of squamous cell carcinoma in renal transplant recipients: a nested case-control study. ( 27584866 )
2016
46
Response to: a network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. ( 27503743 )
2016
47
A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe: response to comments from Prof Dirschka. ( 27501746 )
2016
48
Patient-reported adherence and persistence to topical treatments for actinic keratosis: a longitudinal diary study. ( 27088541 )
2016
49
A 9-month, randomized, assessor-blinded parallel-group study to evaluate clinical effects of a film-forming medical devices containing photolyase and sun-filters in the treatment of cancerization field in comparison with sunscreen in patients after successful PDT for Actinic Keratosis. ( 27167413 )
2016
50
Field Treatment of Actinic Keratosis With Ingenol Mebutate. ( 27168262 )
2016

Variations for Actinic Keratosis

Cosmic variations for Actinic Keratosis:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM45765 TP53 skin,leg,carcinoma,squamous cell carcinoma c.987C>A p.T329T 3
2 COSM45114 TP53 skin,leg,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 3
3 COSM10863 TP53 skin,leg,carcinoma,squamous cell carcinoma c.833C>T p.P278L 3
4 COSM498 HRAS skin,leg,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 3

Expression for Actinic Keratosis

Search GEO for disease gene expression data for Actinic Keratosis.

Pathways for Actinic Keratosis

GO Terms for Actinic Keratosis

Cellular components related to Actinic Keratosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.96 PCNA TP53
2 extracellular matrix GO:0031012 8.92 LUM MMP14 MMP2 TNC

Biological processes related to Actinic Keratosis according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.65 LUM MMP14 PTGS2
2 response to oxidative stress GO:0006979 9.63 MMP14 PCNA PTGS2
3 cellular response to hypoxia GO:0071456 9.5 CFLAR PTGS2 TP53
4 response to X-ray GO:0010165 9.49 TP53 TP63
5 intermediate filament organization GO:0045109 9.43 KRT17 KRT20
6 apoptotic process GO:0006915 9.43 CDKN2A CFLAR KRT20 MCM2 TP53 TP63
7 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.4 CFLAR TMC8
8 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 TP53 TP63
9 replicative senescence GO:0090399 9.26 CDKN2A TP53
10 mitotic G1 DNA damage checkpoint GO:0031571 9.16 TP53 TP63
11 cellular response to UV GO:0034644 8.92 PCNA PTGS2 TP53 TP63

Molecular functions related to Actinic Keratosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 CDKN2A CFLAR KRT17 KRT20 LUM MC1R
2 enzyme binding GO:0019899 9.46 MCM2 PCNA PTGS2 TP53
3 damaged DNA binding GO:0003684 8.8 PCNA TP53 TP63

Sources for Actinic Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....